

Neil H Segal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3854757/publications.pdf>

Version: 2024-02-01

50
papers

13,697
citations

136950

32
h-index

189892

50
g-index

50
all docs

50
docs citations

50
times ranked

19461
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab plus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 122-133.	27.0	3,776
2	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
3	Immunotherapy in colorectal cancer: rationale, challenges and potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 361-375.	17.8	1,039
4	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018, 33, 125-136.e3.	16.8	589
5	PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2363-2376.	27.0	588
6	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2018, 4, e180071.	7.1	404
7	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 286-295.	1.6	397
8	Epitope Landscape in Breast and Colorectal Cancer. <i>Cancer Research</i> , 2008, 68, 889-892.	0.9	373
9	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 849-861.	10.7	368
10	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. <i>JAMA Oncology</i> , 2019, 5, e185896.	7.1	347
11	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2546-2556.	1.6	292
12	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016, 4, 383-389.	3.4	247
13	Classification and Subtype Prediction of Adult Soft Tissue Sarcoma by Functional Genomics. <i>American Journal of Pathology</i> , 2003, 163, 691-700.	3.8	207
14	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. <i>Journal of Clinical Oncology</i> , 2016, 34, 2141-2147.	1.6	204
15	Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1816-1823.	7.0	190
16	Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 513-519.	4.9	186
17	Comparison of Tumor Regression Grade Systems for Locally Advanced Rectal Cancer After Multimodality Treatment. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	179
18	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2020, 10, 1842-1853.	9.4	179

#	ARTICLE	IF	CITATIONS
19	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 391-398.	1.6	156
20	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. <i>Modern Pathology</i> , 2016, 29, 1433-1442.	5.5	144
21	Evolving Treatment of Advanced Colon Cancer. <i>Annual Review of Medicine</i> , 2009, 60, 207-219.	12.2	120
22	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	7.0	118
23	Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy. <i>Ophthalmology</i> , 2017, 124, 1788-1798.	5.2	95
24	False-Positive Elevations of Carcinoembryonic Antigen in Patients With a History of Resected Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 907-913.	4.9	81
25	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. <i>Modern Pathology</i> , 2017, 30, 599-609.	5.5	74
26	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1794-1806.	1.1	69
27	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	6.3	66
28	Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. <i>European Journal of Cancer</i> , 2019, 109, 154-161.	2.8	64
29	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2200-2208.	7.0	51
30	Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1087-1095.	0.8	44
31	Clinical and genetic determinants of ovarian metastases from colorectal cancer. <i>Cancer</i> , 2017, 123, 1134-1143.	4.1	43
32	Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes. <i>Clinical Colorectal Cancer</i> , 2015, 14, 296-305.	2.3	40
33	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 911-919.	1.6	34
34	A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 222-227.	2.3	29
35	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019, 32, 110-121.	5.5	28
36	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	9.4	28

#	ARTICLE	IF	CITATIONS
37	Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1429-1437.	7.0	23
38	FOLFICIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e39-e52.	2.3	21
39	Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant <i>POLE/POLD1</i> Colon Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 817-826.	3.0	18
40	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz015.	2.9	16
41	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. <i>JAMA Network Open</i> , 2021, 4, e2133457.	5.9	16
42	Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. <i>Modern Pathology</i> , 2019, 32, 1551-1562.	5.5	12
43	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2022, 27, 380-388.	3.7	12
44	Translational Considerations on the Outlook of Immunotherapy for Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 92-97.	0.5	6
45	Clinical implications of drug-induced liver injury in early-phase oncology clinical trials. <i>Cancer</i> , 2020, 126, 4967-4974.	4.1	6
46	Is adjuvant therapy for stage II colon cancer worthwhile, and for whom?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008, 5, 422-423.	1.7	5
47	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 167-174.	2.3	3
48	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. <i>Oncolmmunology</i> , 2020, 9, 1841948.	4.6	3
49	Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes. <i>Oncolmmunology</i> , 2022, 11, 2054757.	4.6	3
50	Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity. <i>Clinical Colorectal Cancer</i> , 2022, , .	2.3	2